2024-513463-96-01招募中1 期
Assessment of the exposure-dependent perpetrator characteristics of metamizole on metabolic pathways and the pharmacokinetics of imatinib in healthy volunteers
Universitaetsklinikum Heidelberg AöR1 个研究点 分布在 1 个国家目标入组 36 人开始时间: 2024年9月2日最近更新:
试验速览
- 阶段
- 1 期
- 状态
- 招募中
- 发起方
- 入组人数
- 36
- 试验地点
- 1
研究概览
简要总结
暂无简介。
入排标准
- 年龄范围
- 18 years 至 64 years（18-64 Years）
- 接受健康志愿者
- 是
入选标准
- 未提供
排除标准
- 未提供
研究者
Clinical Trial Unit (Internal Medicine IX, Department Clinical Pharmacology & Pharmacoepidemiology)
Scientific
Universitaetsklinikum Heidelberg AöR
研究点 (1)
Loading locations...
相似试验
招募中
1 期
A PHASE 1, OPEN-LABEL, DOSE ESCALATION AND DOSE EXPANSION STUDY OF CLN-049 FOR THE TREATMENT OF ACUTE MYELOID LEUKEMIA (AML) PATIENTS WITH MEASURABLE RESIDUAL DISEASE (MRD)2023-506572-27-00Florentine Cullinan Corp.97
招募中
1/2 期
A phase I dose-escalation study testing the feasibility and the tolerance of infusion of a third party suicide gene-transduced anti-HLA-DPB1*0401 cytotoxic T cell clone in patients with HLA-DPB1*0401 positive hematologic malignancies and receiving an allotransplant from HLA-DPB1*0401 negative donors2024-515504-39-00Centre Hospitalier Universitaire De Nantes6
招募中
1 期
A first-in-human dose escalation and expansion study with the SIRPα-directed monoclonal antibody BYON4228 alone and in combination with rituximab to evaluate the safety, pharmacokinetics, pharmacodynamics and efficacy in patients with relapsed/refractory CD20 positive B-cell Non-Hodgkin’s Lymphoma (NHL)2024-512390-27-00Byondis B.V.66
招募中
1 期
A study to investigate the safety, the amount that reaches the bloodstream and the effects on the body of JNJ-64619178 in people with advanced cancers2024-515254-24-00Janssen Cilag International74
招募中
1 期
A STUDY TO EVALUATE THE SAFETY, TOLERABILITY, AND PHARMACOKINETICS OF COR-13892024-514853-31-00Corteria Pharmaceuticals80